The present invention relates to a chemotherapeutic agent comprising a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate. The chemotherapeutic agent includes 2.9 mg alexidine dihydrochloride compound and 2.5 mg sodium pentaborate pentahydrate compound, and is obtained by adding 0.5 ml dimethylsulfoxide compound into the alexidine dihydrochloride compound. Upon injecting them to the media containing healthy cells and cancer cells, their effects on cell viability were observed. In accordance with the obtained results; it was observed that when alexidine dihydrochloride solution at concentrations not harming healthy cells is combined with sodium pentaborate pentahydrate, pancreatic cancer cell viability decreased 10% more compared to use of alexidine dihydrochloride alone, and it was realized that this combination can be used as a chemotherapeutic agent for treatment of pancreatic cancer.

The present invention relates to a chemotherapeutic agent comprising a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate. The chemotherapeutic agent includes 2.9 mg alexidine dihydrochloride compound and 2.5 mg sodium pentaborate pentahydrate compound, and is obtained by adding 0.5 ml dimethylsulfoxide compound into the alexidine dihydrochloride compound. Upon injecting them to the media containing healthy cells and cancer cells, their effects on cell viability were observed. In accordance with the obtained results; it was observed that when alexidine dihydrochloride solution at concentrations not harming healthy cells is combined with sodium pentaborate pentahydrate, pancreatic cancer cell viability decreased 10% more compared to use of alexidine dihydrochloride alone, and it was realized that this combination can be used as a chemotherapeutic agent for treatment of pancreatic cancer.

The invention provides compositions and methods of treatment for Dry Eye Syndrome wherein they do not irritate an eye of a human patient who is in need thereof. In particular the invention provides methylglyoxal and Manuka honey in ratios and grades that relieve symptoms and causes of DES without causing irritation to the affected eye(s).

The invention provides compositions and methods of treatment for Dry Eye Syndrome wherein they do not irritate an eye of a human patient who is in need thereof. In particular the invention provides methylglyoxal and Manuka honey in ratios and grades that relieve symptoms and causes of DES without causing irritation to the affected eye(s).

The present invention is directed to compositions and methods for the prevention and treatment of pathological vascular occlusive disorders and related medical conditions. The composition comprising boric acid, sodium chloride, potassium chloride, aluminum sulfate and chamomile.

The present invention is directed to compositions and methods for the prevention and treatment of pathological vascular occlusive disorders and related medical conditions. The composition comprising boric acid, sodium chloride, potassium chloride, aluminum sulfate and chamomile.

The present invention is directed to compositions and methods for the prevention and treatment of pathological vascular occlusive disorders and related medical conditions. The composition comprising boric acid, sodium chloride, potassium chloride, aluminum sulfate and chamomile.

This present invention discloses compositions comprising Dead Sea extract in combination with one or more plant extracts, uses thereof and methods of preventing and/or reducing and/or inhibiting the glycation of one or more biomolecules and/or preventing and/or reducing and/or inhibiting the formation of Advanced Glycation End Products.

This present invention discloses compositions comprising Dead Sea extract in combination with one or more plant extracts, uses thereof and methods of preventing and/or reducing and/or inhibiting the glycation of one or more biomolecules and/or preventing and/or reducing and/or inhibiting the formation of Advanced Glycation End Products.

A formulation for vaginal administration comprising an effective amount of a composition of dried Lactobacillus cells and boric acid, with a carrier. The composition can include one or more antioxidants. Optionally, the composition is in a unit dosage form. Also provided are methods for making and using the composition.